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ABSTRACT 
 
 Objective: To examine the efficacy of an unguided, self-help CBT booklet on 
hot flush and night sweat (HFNS) problem rating, delivered in a work setting. 
 Methods: Women aged 45-60 years, having 10 or more problematic HFNS a 
week, were recruited to a multicentre randomised controlled trial, via the occupational 
health/human resources departments of eight organisations. Participants were 1:1 
randomised to Self-Help CBT (SH-CBT) or No Treatment Waitlist Control (NTWC). 
The primary outcome was HFNS problem rating; secondary outcomes included 
HFNS frequency, work and social adjustment, sleep, mood, beliefs and behaviours, 
and work-related variables (absence, performance, turnover intention and work 
impairment due to presenteeism). Intention-to-treat analysis was used, and between-
group differences estimated using linear mixed models. 
 Results: 124 women were randomly allocated to SH-CBT (n=60) and NTWC 
(n=64). 104 (84%) were assessed for primary outcome at 6 weeks and 102 (82%) at 
20 weeks. SH-CBT significantly reduced HFNS problem rating at 6 weeks (SH-CBT 
versus NTWC adjusted mean difference, -1.49; 95% CI, -2.11 - -0.86; p < 0.001) and 
at 20 weeks (-1.09 95% CI, -1.87 - -0.31; p < 0.01). SH-CBT also significantly 
reduced HFNS frequency at 6 and 20 weeks; improved work and social adjustment, 
sleep, menopause beliefs, HFNS beliefs/behaviours at 6 and 20 weeks; and reduced 
work impairment due to menopause-related presenteeism at 20 weeks, compared to 
the NTWC. There was no difference between groups in other work-related outcomes.  
 Conclusions: A brief, unguided self-help CBT booklet is a potentially 
effective management option for working women experiencing problematic HFNS. 
 
Keywords: Menopause; Work; Menopausal symptoms; Hot flushes; Cognitive 
behaviour therapy; Vasomotor symptoms; RCT 
						 3	
 
What we already know 
 
Menopausal symptoms - hot flushes and night sweats (HFNS) - are particularly 
difficult for women to deal with at work, due to embarrassment, discomfort and some 
aspects of the work environment. Cognitive behaviour therapy (CBT) for HFNS is an 
effective non-medical intervention that can help women to manage these symptoms. 
CBT is effective when delivered in groups or as a self-help booklet, but CBT is not 
generally available to employees in the workplace. 
 
 
What this study adds 
 
This study demonstrates that an unguided self-help CBT approach can be effective in 
reducing the impact and frequency of HFNS experienced by working women. In 
addition, work and social functioning and sleep problems improved to a greater extent 
for those receiving SH-CBT compared to NTWC, and there were benefits to 
wellbeing and reports of somatic symptoms at 20 weeks. While there was no 
difference between the groups in work related outcomes (absence, performance, 
turnover intention), there was an improvement in the SH-CBT group’s perceived 
work ability in spite of menopause-related difficulties (presenteeism) compared to 
NTWC. 
 
 
 
 
 
 
 
 
 
 
 
 
						 4	
 
INTRODUCTION 
 With	rising	employment	rates	for	women	and	an	ageing	profile	of	the	workforce	in	the	UK	and	most	European	countries,	increasing	numbers	of	women	will	be	working	during	their	menopause	transition	and	postmenopause.1,2	As	a	result	there	is	growing	interest	in	improving	the	health	and	wellbeing	of	working	women,	and	retaining	and	increasing	the	numbers	of	experienced	older	women	in	the	workplace.	Recent	recommendations	and	guidance	also	stress	the	importance	of	improving	the	experience	of	menopause	for	working	women.3-5	
There are over 3.5 million women in employment aged between 50 and 65 in the UK6 
and, given that menopause (final menstruation) occurs on average between the ages of 
50–51 and the menopause transition can last for up to ten years,7 a significant 
proportion of female workers will be experiencing menopausal symptoms. While 
many women go through the menopause with few problems, approximately 20-30% 
have troublesome symptoms that impact on their quality of life.8,9 Hot flushes and 
night sweats (HFNS) are the main menopausal symptoms and these are particularly 
difficult to manage in work contexts, due to physical discomfort, social 
embarrassment and the effects of disturbed sleep.10 As well as hot flushes, women 
have been found to report that tiredness, memory/concentration, and loss of 
confidence are problematic at work.11  
Women are generally reluctant to disclose their menopausal status, particularly at 
work, where embarrassment and fear of ridicule is common, and self-control is highly 
valued. Hot flushes may draw attention to menopausal status, particularly during 
formal meetings, when working with men and/or younger adults or in hot 
environments.10,12-13 Discussion about the menopause at work is widely perceived as 
taboo14 and consequently, despite women’s reported experiences, there is a lack of 
awareness about menopause in work settings.  
Although an under-researched area, several cross-sectional studies have examined the 
impact of work environment on experience of menopause, as well as the impact of 
menopause upon work performance. There is some evidence that menopausal 
symptoms can have an effect on work experience, e.g. perceived performance, and 
that certain work situations and physical working environments, such as aspects	of	work	design	and	temperature, and work stress, can increase the intensity of 
						 5	
menopausal symptoms.11,15-21 However, Jack and colleagues in a recent systematic 
review22 concluded that	while	some	working	women	who	had	bothersome	menopausal	symptoms	reported	impaired	work	outcomes,	the	overall	evidence	was	inconclusive.	Moreover,	surveys of work-related stress in the UK23 suggest that 
women aged 45-54 report more work-related stress than mid-aged men or women of 
any other age group. There	are	likely	to	be	complex relationships between work-
related stress and the experience of menopausal symptoms.24    
Griffiths and colleagues11 conducted a study of 896 women employed in ten UK-
based organisations. Women suggested several areas requiring organisational change 
in order to improve women’s experience of menopause at work; these included: (i) 
greater awareness among managers about menopause as a possible occupational 
health issue, (ii) flexible working hours, (iii) access to information and sources of 
support at work, and (iv) attention to work place temperature and ventilation. The 
current study aims to address (iii) as outlined in the study protocol paper.25 
Hormone therapy (HT) is an effective medical treatment for menopausal symptoms26 
but not all women want to take it due to contraindications and personal preference. 
Cognitive behaviour therapy (CBT) is recommended for anxiety and depression 
during the menopause26 and a CBT intervention has been developed to help women to 
manage HFNS,27-30 that is based on a theoretical model31 supported by recent 
empirical studies.32-34 HFNS can be potentiated by stress and are exacerbated by 
negative beliefs and behavioural reactions. The intervention therefore includes 
psychoeducation and evidence-based CBT strategies to reduce stress, and to manage 
hot flushes, night sweats and sleep. CBT for HFNS has been found to be effective in 
reducing the impact of HFNS, i.e. how problematic they are, in several clinical 
trials,27-29 frequency of night sweats27 and physiologically monitored HFNS.35 CBT 
was recommended as an effective treatment for vasomotor symptoms in a recent 
position statement on non-hormonal interventions, by the North American Menopause 
Society.36  
Group CBT and self-help CBT (a self-help booklet containing the same information 
with a breathing/relaxation CD) formats for HFNS have been shown to be equally 
effective in reducing the impact of HFNS;27 however, group CBT had more impact on 
mood and quality of life. Self-help CBT has also been found to produce similar levels 
of improvement when delivered with minimal guidance.30 Although CBT 
						 6	
interventions for HFNS are available in self-help and group formats,37-38 there have 
not been any previous work based trials and CBT interventions for HFNS are not yet 
widely accessible to women at work.  
We hypothesised that CBT will be more effective than no treatment in: (i) 
reducing the impact of HFNS (problem-rating),11 and (ii) reducing HFNS frequency, 
moderating menopause beliefs, HFNS beliefs and behaviours, improving mood, 
sleep, work and social adjustment, and work outcomes (work absence, presenteeism, 
job performance, and turnover intention).   
 
 
 
METHODS 
 
 The	trial	is	reported	in	accordance	with	the	CONSORT	guidelines	for	randomised	controlled	trials39	and	is	described	in	detail	in	a	trial	protocol	paper25 (trial registration: ClinicalTrials.gov identifier: NCT02623374).	
Ethical approval was obtained from Kings College London Research Ethics 
Committee (Psychiatry, Nursing and Midwifery Research Ethics Subcommittee, 
reference: RESCMR-14/15-0475).  
 
Participants and procedure 
Eight organisations, from public and private sectors, participated in the study. 
Organisations volunteered to take part in response to talks given at conferences or 
other occupational health-related events, and by direct contact. Each participating 
organisation had a ‘gatekeeper’ who was responsible for disseminating recruitment 
materials (posters, leaflets, emails) within the organisation. The research team also 
gave presentations within organisations to raise awareness of the project and invite 
eligible women, who self-referred, to take part.  
 Participants were menopausal women with problematic HFNS. Inclusion 
criteria were: women, employed within participating organisations, English speaking, 
aged 45-60 years, having problematic HFNS for at least 2 months (scoring above 2 on 
the Hot Flush Rating Scale7, minimum frequency of 10 a week), and having no 
						 7	
current major physical or mental health problems that would compromise 
participation. 
 Potential participants contacted the trial coordinator by telephone or email and 
were provided with a verbal description of the study, and if interested to proceed, 
were screened by telephone. Those eligible were sent a participant information sheet, 
consent form and a baseline questionnaire, with a self-addressed and stamped 
envelope to return the signed and dated consent form, and questionnaire. Data were 
collected at Kings College London and participating organisations. Participants who 
returned signed consent and baseline questionnaires were randomly allocated into one 
of two arms: treatment or control (figure 1). Randomisation was performed using 
Microsoft Excel with a ratio of 1:1, stratifying by recruiting centre. Participants 
allocated to the treatment group were posted the self-help booklet. Data entry was 
performed by a researcher blind to group allocation and statistical analysis by the trial 
statistician who was also blind to treatment condition. 
 Participants were asked to completed follow-up questionnaires at 6 weeks and 
20 weeks post-randomisation. A prize draw of £50 Amazon voucher (or similar) was 
offered as an incentive to complete all three questionnaires. The participants in the 
Self-help CBT arm were also invited to take part in an evaluation interview via 
telephone after returning the final follow-up questionnaire.  
   
Intervention 
 The Self-Help CBT booklet (SH-CBT) was adapted from the self-help booklet 
used in the MENOS2 trial27,37 (see protocol paper25). The booklet was adapted and 
shortened, with additional sections covering work stress and how to discuss 
menopause at work. Pilot work was conducted to assess the acceptability, content and 
format of the intervention and questionnaires, as well as the delivery method. We also 
explored potential barriers and difficulties for women using the SH-CBT intervention. 
Telephone interviews were conducted with working menopausal women (n=10) who 
had been sent the booklet from four of the participating organisations. Women noted 
that having the word menopause on the front cover might cause embarrassment and 
reduce use of the booklet. The preferred delivery of the self-help intervention and 
questionnaires was in paper form, although several mentioned that an online option 
might be preferred, by some women. Feedback was addressed; modifications included 
adding content about how to have conversations with line managers at work, an 
						 8	
infographic that can be given to a line manager when attempting to have the 
discussion, removal of the word menopause from the front page, and adding examples 
from work situations throughout the booklet. The final revised booklet and 
questionnaires were also reviewed by an advisory group (comprising working 
menopausal women, academic researchers, trade union representatives, employers) 
and minor amendments/corrections made.   
 The final SH-CBT intervention was an A5 sized, colour booklet with 
instructions and four chapters (with information, exercises and homework tasks) to be 
completed over four weeks. Chapters covered psycho-education about menopause and 
HFNS, stress management, breathing/relaxation, and learning cognitive and 
behavioural strategies to help manage HFNS, stress and sleep, with individual goal 
setting and weekly homework. A relaxation and breathing exercise was also provided 
on a CD, which was included with the booklet, together with an infographic.  
 Participants in the no treatment waitlist control (NTWC) condition did not 
receive SH-CBT during the treatment phase but were sent the SH-CBT booklet after 
the 20 week assessment, off-trial. All participants were able to access their general 
practitioner and other health care options.  
 
Measures 
 Demographic information (age, ethnicity, height, weight, education, 
relationship and 
employment status), smoking, alcohol intake and exercise behaviour, menopausal 
status (menopause transition/postmenopause), treatment experience, and work 
variables (type of job, working hours, shift working, age and gender of work 
colleagues) were recorded at baseline. All data was self-reported.  
 
Primary outcome 
 The primary outcome was HFNS Problem Rating10 at 6 weeks and 20 weeks 
post randomisation. Problem rating was measured by a subscale of the Hot Flush 
Rating Scale as used in the MENOS2 trial,27 containing three items: “To what extent 
do you regard your flushes/sweats as a problem?”; “How distressed do you feel about 
your hot flushes?” and “How much do your hot flushes interfere with your daily 
routine?” Items are measured on a 10 point scale ranging from 1 to 10, with high 
scores indicating more problematic hot flushes; a two point change on this scale is 
						 9	
generally considered clinically significant.27-28 Cronbach alpha (α) for this measure 
was 0.83 at baseline. 
 
Secondary outcomes 
HF Frequency: HFNS frequency was measured with the Hot Flush Rating Scale7, 
which records of the number of HFNS experienced in the previous week.  
 HFNS Beliefs and Behaviours: A shortened version of the Hot Flush Belief 
Scale40 and the Hot Flush Behaviour Scale41 were used (see supplementary file in 
Protocol paper25). Beliefs were measured using a mean score of 10 items, producing 
three sub-scales: beliefs about HF in a social context (at baseline, α=0.89); 
coping/control over HF (α=0.73); and beliefs about NS and sleep (α=0.60). 
Behaviours were measured from a mean score of 6 items producing two sub-scales: 
avoidance behaviour (at baseline, α=0.80) and positive behaviours (α=0.48). 
Responses ranged from 0 (strongly disagree) to 5 (strongly agree).   
 The Menopause Representations Questionnaire (MRQ)42 was used to assess 
women’s cognitive representations of the menopause with respect to identity 
(attribution of symptoms to menopause), consequences, and control/cure. The MRQ 
comprising of 37 items, using a 5 point Likert scale ranging from strongly agree (5) to 
strongly disagree (1). Mean scores on the subscales are calculated. Cronbach alpha for 
the subscales at baseline were: identity .80, negative impact .74, new phase .67, relief 
.47, control/cure .77. 
 The Revised Women’s Health Questionnaire (WHQ)43 was used to measure 
perceptions of physical and emotional health. The revised WHQ has 23 items and has 
been found to have the same if not improved psychometric properties than the original 
in a recent study in a recent study.44 The following subscales examined in this study: 
anxiety/depression, wellbeing, somatic symptoms sleep problems, and 
memory/concentration (baseline α=0.62, 0.66, 0.68, 0.62, 0.72, respectively).  
A single item measure of sleep quality was added from the Pittsburgh Sleep Quality 
Index (PSQI),45 which is a self-rated questionnaire assessing sleep quality over a 1-
month time interval using a 4-point Likert scale (1= “Very bad” to 4 = “Very good”). 
The Work and Social Adjustment Scale (WSAS) 46 is a five-item scale used to 
measure functional impairment at home, work and in social situations attributed to a 
specific problem (menopausal symptoms). Items are measured from 0 (no 
						 10	
impairment) to 8 (very severely impaired) and summed to produce a final score out of 
40 (α=0.88). 
 
Work related outcomes: 
Absenteeism is the total number of days affected by work absence in the last 4 weeks 
attributed to the menopause. The number of days off work due to symptoms, the 
number of days arrived to work late, and the number of days left work early due to 
their menopause were summed to create this variable.  
Job performance was measured using a single item 5-point Likert scale, 1 (poor) to 5 
(excellent) where participants were asked to rate their perceived performance in 
relation to others. 
The Stanford Presenteeism Scale47 was used to measure menopausal women’s 
perceptions of being physically present at their jobs, but experiencing decreased 
productivity and below-normal work quality due to their menopause. Using 6-items, 
the average scores on a five point Likert-type scale, ranging from strongly disagree 
(1) to strongly agree (5) were calculated (α=0.79). Higher scores suggest low 
perceived work impairment due to the menopause. 
Turnover intention was measured using an existing 4-item measure48, with 5-point 
Likert scales, to assess the employee’s intention to leave the organisation (α=0.81). A 
higher score suggests a greater intention to leave the organisation.  
  Any medical, non-medical and over the counter treatments used and health 
services accessed for menopause during the treatment phase (post randomization) 
were logged at the 20 week follow-up. Analysis	of	additional	variables:	attitude	to	menopause	at	work,	disclosure,	job	stress	and	job	satisfaction,	resilience,	intention	to	reduce	working	hours	or	stop	working	because	of	the	menopause,	will	be	reported	elsewhere,	together	with	a	mediation	analysis.	
 
						 11	
Sample size  
Based on previous studies,27-28 a total sample size of 80 participants, 40 per arm, are 
required to detect 2 points difference in HFNS mean score at 6 weeks using 
regression analysis controlling for baseline level of the outcome, with a 90% power at 
2 tailed significance 0.05 level, assuming equal SD (3.0) for both groups and 
correlation between baseline and follow up measures at 0.4 for the purpose of being 
conservative. After taking into account 20% loss to follow up rate, a total sample size 
of 100 is required, 50 per arm.  
 
Statistical analysis 
Group comparisons were carried out using the (modified) intention-to-treat principle, 
with participants providing data on at least one post-randomisation assessment 
analysed in the group to which they were randomised. Treatment effects for the 
primary (HFNS problem rating) and secondary outcomes were estimated using linear 
mixed models. The post-randomisation values of the outcome variables at 6 and 20 
weeks were included as the outcome. Indicator variables for time, group, and a time 
by group interaction term and a recruiting centre indicator variables were included as 
covariates to allow treatment effects to vary by group at the two post-randomisation 
assessments. A random intercept for each participant was included to account for the 
repeated assessment of the outcome variable. Adjusted mean differences are presented 
unstandardised (i.e. original scale units) and as a standardised mean differences (i.e. 
standard deviation units; SMD) where the adjusted mean difference is divided by the 
pooled standard deviation of the outcome at baseline. 
Prior to estimating the treatment effects, the suitability of the variables for 
analysis was considered by inspecting their distributions by group at each time points. 
Residual diagnostics were performed for the mixed effects models to confirm the 
assumption that outcome variables follow an approximately normal distribution was 
not violated.    
The maximum likelihood estimator employed produces unbiased and efficient 
estimates of the treatment effect when missing outcome data arises at random 
conditional on the covariates included (i.e. missing at random). Sensitivity analyses 
were performed by comparing the treatment effect estimates to those where missing 
outcome assessments were imputed using the last observed value of the outcome (i.e. 
last observation carried forward). In addition, for the primary outcome, additional 
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sensitivity analysis was performed using a pattern-mixture model approach to 
determine the impact of a range of reasonable missing data scenarios on the treatment 
effect estimate.49 
The recorded evaluation interviews were transcribed and a thematic content analysis 
was performed using the software NVivo (version21). Categories were developed 
under four main themes, including the impact of the intervention, reasons for the 
impact and for no impact experienced, perceptions of the intervention’s content and 
delivery, and suggestions for improvement.  
 
RESULTS 
Participants 
124 participants were randomised from eight, public (n=6) and private sector (n=2), 
organisations in the UK. Of these, 106 (85.5%) completed at least one post-
randomisation assessment and were included in the (modified) intention-to-treat 
analysis. Overall attrition was below 20%, but it was higher in the SH-CBT group 
compared to the NTWC group with 60 (93.8%) and 46 (76.7%) included in the 
analysis, respectively. Participant flow through the trial is shown in figure 1. 
Table 1 presents demographic information at baseline. Women were, on average, 54 
years old and 70% were of white ethnicity. The sample was fairly healthy, with the 
majority rating their general health as good to excellent (85%). Over two-thirds were 
non-smokers and were drinking less than 7 units of alcohol per week. Most women 
exercised at least twice a week (68%). Women generally did not have a current 
mental or physical health problem (85%), nor were receiving treatment for breast 
cancer (95%). They had experienced their last menstrual period (LMP) on average 4 
years before entering the study. Four per cent (n=5) were taking hormone therapy 
(HT), and 18% (n=20) were prior HT users; 32.5% (n=40) were taking over the 
counter remedies or medication for the menopause and 23% (n=29) had sought 
medical help for menopause in the past 6 months.   
Just over three-quarters (83%) of women worked full-time, with regular hours, not 
shift work. The majority worked in non-manual jobs (82%), with both male and 
female colleagues (65%) having a mixed age range (73%). At baseline, the number of 
days affected by absence (including whole days, arriving to work late, leaving work 
early), that women attributed to menopause averaged 2 days (mean=1.80, sd=4.22) at 
baseline, over the past 4 weeks. Half (50.8%, n=63) had disclosed that they were 
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going through the menopause to a line manager, but only 9.7% (n=12) disclosed that 
menopause was a reason for any work absence. The majority rated their work 
performance as very good or excellent (79.9%, n=91).  
[INSERT TABLE 1 AND FIG 1 HERE] 
 
Outcomes   
At baseline women reported having an average of 56.24 (range 0-245) HFNS per 
week, and these were rated as problematic (mean 6.5/10); the average duration of 
HFNS was 35 (SD=32.6) months (range 2 to 192 months). 
 
Primary outcome 
Unadjusted and baseline adjusted mean differences are shown in Table 2. The 
adjusted mean difference in the primary outcome HFNS Problem-rating, controlling 
for baseline level, was -1.49 (p<0.001) in favour of the SH-CBT group at 6 weeks, 
and -1.09 (p	<0.01) at 20 weeks. These differences translate to a moderate to large 
effect sizes of d=-0.77 and -0.56, respectively (Table 2 and Fig 2).  
No selection bias due to differential attrition by baseline problem rating was apparent. 
There was only a small difference in HFNS Problem-rating mean baseline scores in 
the NTWC group between those completing (N=60) and not completing (N=4) at 
post-randomisation assessment, and therefore included in the analysis: 6.80 versus 
7.33. Similarly, there was only a small difference in baseline scores in the SH-CBT 
group between those completing (N=46) and not completing (N=14) at post-
randomisation assessment: 6.25 versus 6.10. Those who did not complete were 
significantly more likely to be of non-white ethnicity (Pearson chi square=4.38, p	<0.05), not in a relationship, chi-squ=5.61, p	<0.05) and to score higher on HFNS 
avoidance behaviour (Mean rank=85.89) to those included (Mean rank=58.53), U = 
1375, z = -3.056, p	<0.01, and not receiving treatment for any major physical or 
health problem (Chi square=6.63, p	<0.01). There were no significant differences in 
HFNS frequency or problem rating.  
Sensitivity analysis was conducted to determine the impact of missing data at post-
randomisation assessments on the estimated treatment effect size at 6-weeks. The last 
observation carried forward approach including all randomised participants indicated 
a more conservative effect size of 0.51. A pattern-mixture model approach was 
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employed to examine the sensitivity of the treatment effect as a result of the higher 
attrition in the SH-CBT group. This suggested that those with missing data in the 
intervention group would have had to experience worsening of 3 points on average 
relative to their baseline values to reduce the treatment effect to non-significant. Such 
a difference appears implausible.  
 [INSERT TABLE 2 and FIG 2 HERE] 
 
Secondary outcomes 
 In addition to the significant moderate to large effect on the primary outcome 
there was a significant effect on HFNS frequency at the 6 week and the 20 week 
assessment, effect sizes 0.39 and 0.31 respectively. HFNS frequency was highly 
variable; total HFNS frequency reduced on average by 24% SH-CBT, 0.5% NTWC at 
6 weeks, and by 35.5% SH-CBT and 15% for NTC at 26 weeks.  
There was a significant effect of SH-CBT on levels of functioning measured by the 
Work and Social Adjustment Scale (WSAS)46 at both 6 and 20 week assessments. 
There were significant group differences in WHQ wellbeing and somatic symptom 
scores at 20 weeks, and in sleep problems at 6 and 20 weeks. Similarly, significant 
improvements in sleep quality were recorded at 6 and 20 weeks as assessed by the 
Pittsburg Sleep Quality Index.45 (see Table 2 and Fig 2). 
 Large and moderate significant effects were observed for the beliefs about 
menopause and beliefs/behaviours about HFNS. SH-CBT participants viewed 
menopause as more controllable and curable and as a new phase (MRQ control/cure 
and new phase subscales) significantly more than NTWC at both 6 and 20 week 
assessments. Effects on other MRQ subscales were small and generally non-
significant. Moderate to large significant effects were observed for the three HFNS 
beliefs scales and for the positive behaviours subscale. The effect on avoidant 
behaviours was small and non-significant. 
In relation to work variables, effects were generally small and non-significant for 
absence (days affected by any absence in past 4 weeks and attributed to menopause 
including whole days, arriving to work late, leaving work early), performance, and 
turnover intention. However, for presenteeism (Stanford Presenteeism Scale47) at 20 
weeks, the effect of SH-CBT compared to NTWC was significant and approaching a 
large effect size. Those receiving SH-CBT had higher scores at 20 weeks than the 
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NTWC group, indicating lower perceived work impairment due to the menopause for 
the SH-CBT group. 
	
Use	of	services	and	medication		 Since	starting	the	study	(randomisation	to	20	week	assessment),	14%	(n=6)	of	the	SH-CBT	and	15%	(n=9)	of	the	NTWC	participants	had	sought	medical	help,	on	average	once,	for	menopause	symptoms	-	a	nonsignificant	difference.	One	woman	(SH-CBT	group)	was	prescribed	antidepressants	for	anxiety/mood	swings;	in	the	NTWC	group,	two	were	prescribed	HT,	one	the	contraceptive	pill	and	two	changed	type	of	hormone	therapy.	Eight	(NTWC=7,	SH-CBT=1)	had	used	non-medical	or	herbal	treatments	since	starting	the	study:	homeopathy	(n=1	NTWC),	evening	primrose	oil	(n=3	NTWC),	red	clover	(n=1	NTWC),	sage	tablets	(n=1	NTWC)	and	Menopace,	one	participant	from	each	group).		
Adherence	and	acceptability			 At	the	6	week	follow-up	assessment,	61%	(n=27)	of	SH-CBT	participants	had	read	the	entire	self-help	booklet,	and	an	additional	21%	(n=9)	more	than	half.	The	majority	(82%,	n=32)	had	used	the	relaxation/breathing	exercise	at	least	1-2	times	a	week	or	more,	at	the	onset	of	a	hot	flush	(82%,	n=37)	and	to	help	manage	a	stressful	situation	at	work	(71%,	n=25).	Similarly,	at	20	weeks,	65%	(n=28)	of	SH-CBT	participants	had	read	all	of	the	self-help	booklet,	and	26%	(n=11)	more	than	half.	Relaxation/breathing	was	reportedly	still	being	used	by	79%	(n=33)	at	least	1-2	times	a	week	or	more.		 At	6	weeks	89.4%	(n=42)	rated	the	self-help	booklet	as	being	helpful	in	coping	with	their	menopause	symptoms	at	work;	23.4%	(n=11)	moderately	and	31.9%	(n=15)	very/extremely	helpful.	At	the	20	week	assessment	88.1%	(n=35)	rated	the	self-help	booklet	as	helpful	in	coping	with	their	menopause	symptoms	at	work;	26.2%	(n=11)	moderately	and	45.2%	(n=19)	very/extremely	helpful.			
Evaluation	interviews		 Twenty-seven	women	were	interviewed	at	the	end	of	the	trial	from	the	intervention	group.	We	originally	intended	to	select	50%	of	transcripts	for	
						 16	
analysis,22	but	as	only	27	women	took	part	in	interviews,	all	their	data	were	included.	The	majority,	82%,	felt	that	the	intervention	had	impacted	positively	on	their	experience	of	HFNS,	48%	mentioning	a	reduction	specifically	in	HFNS	frequency.	Positive	benefits	were	reported	to	life	in	general	(63%),	and	to	working	life	(52%).	Since	the	start	of	the	trial,	37%	had	talked	about	their	menopause	to	their	line	manager.			 Reasons	given	for	improvements	in	general	to	life	included:	changing	perceptions	about	the	menopause	and	having	a	better	understanding,	exercising	self-care,	and	having	the	confidence	to	talk	and	to	be	open	about	their	menopause.	Positive	changes	to	working	life	were	attributed	to	addressing	HFNS	triggers	identified	during	the	SH-CBT,	feeling	less	bothered	or	focused	on	symptoms,	using	the	breathing	techniques	and	letting	go,	and	also	having	more	confidence	at	work.	Participants	who	did	not	experience	any	impact	from	the	intervention	stated	it	was	because	they	were	already	doing	things	to	help	manage	symptoms	anyway	they	did	not	follow	the	self-help	or	their	HFNS	had	improved.			 	In	terms	of	the	self-help	booklet	content,	the	main	aspects	that	the	participants	mentioned	as	being	helpful,	were	that	it	was	informative,	particularly	the	materials	on	managing	HFNS,	e.g.	addressing	thoughts,	the	CBT	approach,	and	identifying	triggers;	they	also	liked	the	dairies	and	interactive	elements	of	the	booklet	(e.g.	exercises	to	complete).	Other	helpful	aspects	included	having	testimonials	and	perceptions	of	others	presented	in	the	booklet,	the	breathing	exercise	and	CD,	the	goal	setting	section,	as	well	as	the	general	design	and	structure	of	the	booklet.	Approximately	two	thirds	liked	the	hard-copy	format	of	the	booklet;	however,	some	thought	that	having	an	online	version	or	an	app	for	smart	phones	could	be	offered	in	the	future.	
 
DISCUSSION 
 The	aim	of	this	multicentre	study	was	to	investigate	the	impact	of	a	brief,	unguided,	self-help	CBT	intervention	on	HFNS,	for	women	having	problematic	menopausal	symptoms	in	the	work	context.	When	compared	to	a	no-treatment	control	group,	unguided	self-help	CBT	significantly	reduced	HFNS	problem	
						 17	
rating	with	moderate	to	large	effect	sizes	and	improvements	were	maintained	at	20	weeks	post-randomisation.	These	results	are	consistent	with	findings	from	previous	randomised	controlled	trials	of	CBT	for	HFNS,	when	delivered	in-group	and	guided	self-help	booklet	formats.	27-30	However, it is noteworthy that this study 
implemented a considerably briefer version of SH-CBT with no additional support, 
and in a work, rather than a clinical context.  	 HFNS	frequency	also	reduced	at	both	time	points	and	group	differences	were	significant	at	both	6	weeks	and	20	weeks.	Percentage	reduction	in	frequency	of	24%	(6	weeks)	and	35.5%	(20	weeks)	was	broadly	similar	to	that	found	in	previous	studies	of	guided	self-help;	27,30	relatively	small	changes	were	evident	for	the	NTWC	group. In	the	MENOS	2	trial27	HFNS	frequency	assessed	by	sternal	skin	conductance	monitoring	also	significantly	improved	following	CBT,	suggesting	that	changes	might	occur	at	both	subjective	and	physiological	levels.35	 The	significant	improvements	on	the	Work	and	Social	Adjustment	Scale	(WSAS)	scores	at	both	6	weeks	and	20	weeks	post-randomisation	compared	to	the	control	group,	provide	evidence	of	the	secondary	benefits	of	SH-CBT	to	functioning	at	work, home, leisure, and in social situations. The WSAS is routinely 
used in primary care psychology services in the UK and has been found to reflect a 
distinct social functioning factor and to be sensitive to treatment effects.50 There were 
significant group differences in wellbeing and somatic symptoms at 20, but not at 6, 
weeks; but not anxiety/depression nor memory/concentration subscales of the Revised 
WHQ.  However, WHQ sleep problems subscales scores and sleep quality 
significantly improved following SH-CBT at 6 and 20 weeks. The CBT intervention 
includes advice and strategies to improve sleep and CBT is an effective treatment for 
insomnia.51  
CBT for HFNS targets cognitions (catastrophic or shameful thoughts in social 
contexts, worries about the consequences of night-time wakening), overly negative 
beliefs about menopause, behavioural reactions, and stress/well-being. Mediation 
analyses of previous trials have shown that CBT appears to work by changing 
symptom perceptions and cognitive appraisals (women’s perceptions, attitudes and 
beliefs about menopause and symptoms) and well as using helpful behavioural 
strategies.33-34 Consistent with this work, we found significant changes	in	beliefs	and	behaviours	about	HFNS	following	SH-CBT,	suggesting	that	the	treatment	is	
						 18	
targeting	relevant	cognitions	and	behaviours.	More	general	beliefs	about	the	menopause,	reflected	in	MRQ subscales negative impact, control/cure and new 
phase subscales,	also	showed	significant	between	group	differences	at both 6 and 
20 week assessments.	 
The current findings therefore lend support to the cognitive model of HFNS.31 The 
social aspects of these beliefs – relating to social meanings about the menopause and 
concern about other people’s views when having hot flushes - are relevant because 
women report embarrassment and fear of ridicule particularly in work contexts.10,12,13 
More positive/neutral beliefs about menopause, e.g. that symptoms are controllable 
and that menopause can herald a new life phase, are associated with more positive and 
helpful beliefs about HFNS, e.g. that others may not think negatively about them, that 
women have strategies to cope with them; and, in turn, positive and neutral beliefs 
about HFNS are associated with less problematic HFNS.32,40-41 The	majority	of	women	(80%)	rated	their	work	performance	as	very	good	or	excellent	at	baseline.	Presenteeism,	using	the	Stanford Presenteeism Scale,45 
measures menopausal women’s perceptions of productivity and work impairment due 
to their menopause while being physically present at work. Higher scores suggest low 
perceived work impairment due to the menopause; i.e. women are at work and 
managing any work impairment so that their performance is not affected. The SH-
CBT group obtained significantly higher scores than NTC at 20 weeks. It is possible 
therefore that the strategies learnt from the SH-CBT might enable women to manage 
their HFNS so that they have less impact on their work. HFNS become less 
problematic and social and work functioning improves. The relationships between 
improvements in HFNS and presenteeism will be explored in a future publication.  
The	lack	of	impact	on	additional	work	outcomes	may	relate	to	the	timeframes	used	in	the	trial.	It	is	possible	that	20	weeks	post-randomization,	or	approximately	16	weeks	post	treatment,	was	insufficient	time	for	changes	in	work	adjustment	to	occur.	For	example,	the	significant	between	group	difference	in	presenteeism	was	only	found	at	20	weeks	and	not	at	6	weeks.		Alternatively,	problematic	HFNS	may	not	impact	on	all	work	outcomes	in	similar	ways.	The	workplace	is	a	complex	environment;	the	experience	of	HFNS	may	interact	with	several	employee	related	and	work-related	factors.	A	review	by	Jack	and	colleagues22	identified	that	the	work	environment,	both	physical	and	
						 19	
psychosocial,	may	influence	women’s	experience	of	menopause.	Further	analysis	of	the	potential	moderating	effect	of	a	number	of	work	related	factors	(work	environment,	job	satisfaction	and	job	stress)	is	planned.		 Overall,	our	results	suggest	that	an	unguided,	self-help	CBT	approach	may	be	efficacious	as	a	low	intensive	treatment	option	for	working	women	with	problematic	menopause	symptoms.	The levels of frequency and problem-rating 
HFNS at baseline were very similar to the levels of well women and breast cancer 
patients recruited into clinical trials,27-29 and the improvements following this low-
intensity version of SH-CBT were robust and sustained. Comparable recommended 
non-hormonal treatments for HFNS involve several sessions of treatment, e.g. 5-12 
sessions of hypnosis and 8 sessions of mindfulness:36 while hormonal and non-
hormonal medical treatments involve appointments and ongoing prescription 
charges. The intervention involves no health professional time and is likely therefore 
to be cost effective; however, a health economic analysis is recommended. The 
intervention appeared to be acceptable in terms of feedback reported during 
interviews, and the women’s reports on what was helpful were consistent with 
qualitative data collected during the MENOS2 trial.52 
 Strengths	and	limitations		 The	trial	was	adequately	powered,	there	were	no	adverse	events,	relatively	low	levels	of	attrition	during	the	trial	period,	and	adherence	to	the	SH-CBT	was	reasonable.	The	SH-CBT	was	piloted	and	modified	in	response	to	feedback.	Unexpectedly,	dropouts	were	higher	in	the	SH-CBT	than	the	NTWC	condition,	which	is	a	limitation.	Most	women	in	the	SH-CBT	arm	who	dropped	out	reported	time	pressures	as	the	main	problem	for	not	completing	the	self-help	intervention	and	questionnaires.	It	is	possible	that	the	women	in	the	NTWC	arm	may	have	been	more	likely	to	persist	in	the	study	because	they	were	expecting	to	obtain	the	SH-CBT	off	trial	at	the	end	of	the	study.	Participants	who	dropped	out	were	more	likely	to	be	non-white,	not	in	a	relationship,	to	have	higher	baseline	HFNS	avoidance	behaviour	scores,	and	not	having	any	current	treatment	for	any	major	physical	or	mental	health	problem.	In	previous	trials,	ethnicity	either	did	not	moderate	the	effects	of	CBT,34	or	when	it	did	it	was	women	of	non-white	ethnicity	who	were	more	likely	to	benefit	from	CBT.33	It	is	
						 20	
possible	that	the	self-help	booklet	was	less	appealing	or	acceptable	to	some	women,	who	may	have	had	less	support,	and,	for	others,	being	avoidant	about	HFNS	could	reflect	a	more	general	strategy	(i.e.	avoiding	the	self-help	book	designed	to	help	manage	HFNS).	Pilot work was conducted to assess the 
acceptability, content and format of the intervention and questionnaires, as well as 
the delivery method, and adjustments made, but we did not actively	target	women	from	a	range	of	ethnic	groups.	Further	exploration	is	needed	into	the	acceptability	of	the	booklet,	its	format,	and	the	level	of	individual	or	group	support	in	different	organisations,	in	order	to	increase	adherence	to	the	intervention.			
 Assessment	of	work	outcomes	relied	on	subjective	rather	than	objective	measures.		However,	obtaining	formal	sickness	absence	data	and	standard	measurements	of	job	performance	for	different	job	roles	in	heterogeneous	workplaces	is	a	complex	matter	and	was	beyond	the	scope	of	this	study.	Further,	this	might	have	been	perceived,	by	participants,	as	compromising	the	anonymous	nature	of	their	responses.		Implications	and	future	research		 The	trial	findings	have	implications	for	various	key	stakeholders;	employers,	occupational	health	professionals,	trade	union	representatives,	and	other	professionals	with	a	role	in	workplace	health	and	wellbeing,	may	wish	to	make	self-help	CBT	available	to	staff	who	have	bothersome	menopause	symptoms.	Similarly,	policy	makers	should	ensure	that	sufficient	awareness	and	provision	of	information	and	help	is	offered	to	staff	who	may	be	experiencing	menopause-related	difficulties	at	work,	in	line	with	recent	recommendations.1,3-5,53	 Several	suggestions	for	future	research	have	been	mentioned	above.	The	format	and	level	of	detail	of	the	provision	of	information	for	working	women	could	be	considered	in	future	research;	for	example,	whether	briefer	information	is	made	available	for	all	staff,	with	SH-CBT	offered	to	those	who	have	problematic	symptoms.	The	needs	and	working	environments	of	organisations	are	likely	to	vary.	SH-CBT	is	available	in	book	format	37	and	workshops	or	groups	could	be	offered	using	the	manual	for	health	
						 21	
professionals.38	It	may	also	be	of	interest	to	explore	the	effect	of	self-help	for	other	symptoms	reported	by	women	at	work	(e.g.	confidence,	fatigue)	in	more	detail,	and	to	clarify	the	extent	to	which	these	are	affected	by,	or	interact	with	for	example	work	stress	and	HFNS.	Recommendations	for	improving	the	experience	of	menopause	at	work	include	changes	at	an	individual	level	and	at	an	organisational	level.3-5	Similarly,	we	would	predict	that	the	SH-CBT	intervention	for	women	with	troublesome	menopausal	symptoms	might	be	more	effective	when	offered	in	the	context	of	a	broader	strategy	to	improve	awareness	about	menopause	in	general,	to	reduce	stigma	and	to	make	appropriate	changes	to	work	environment.53			CONCLUSIONS	To	our	knowledge	this	is	the	first	study	to	develop	and	evaluate	an	unguided,	self-help	intervention	specifically	to	help	menopausal	women	to	manage	HFNS	in	the	workplace.	The	results	suggest	that	SH-CBT	is	an	effective	and	acceptable	low-intensity,	non-medical	intervention	for	problematic	HFNS	that	has	additional	effects	on	work	and	social	adjustment	and	on	presenteeism.	The	study	is	timely,	and	has	important	implications	for	employers	and	other	stakeholders	who	have	a	responsibility	to	provide	resources	for	working	women.					
"This is a non-final version of an article published in 
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Table 1.  Baseline demographics, health, and job status of participants 
Participant 
demographics  
SH-CBT 
(N=60) 
NTWC 
(N=64) 
Total  
(N=124) 
Age  Mean (SD) 54.04 (3.17) 54.10 (3.53) 54.09 (3.4) 
 
Ethnicity 
 
White British 
 
42 (70.0% 
 
45 (71.4%) 
 
87 (70.7%) 
 Black British  11 (18.3%)  14 (22.2%) 25 (18.3%) 
 Other 7 (11.7%) 4 (6.4%) 11 (8.9%) 
 
Menopause transition 
Postmenopause 
 
11 (20%) 
44 (80%) 
 
20 (35.7%) 
36 (64.3%) 
 
 
31 (27.9%) 
80 (72.1%) 
Last menstrual period 
(months) Mean (SD) 
48.29 (54.16) 35.68 (51.69) 42.04 (53.09) 
Hysterectomy 10 (17.0%) 6 (10.0%) 17 (14.0%) 
Oophorectomy 3 (5.0%) 6 (10.0%) 9 (7.0%) 
 
Menopausal 
status 
 
 
 
 
 
     
Single 11 (18.3%) 15 (25%) 27 (21.8%) 
Married/Partnered 42 (70.0%) 37 (57.8%) 79 (63.8%) 
Divorced/Separated/ 
Widowed 
 
7 (11.7%) 11 (17.2%) 18 (14.5%) 
Left school at 16  16	(26.7%) 17	(28.3%) 34	(28.1%) 
Left school at 18 7	(11.7%) 4	(6.7%) 11	(9.1%) 
Degree 37	(61.6%) 39	(65%) 76	(62.8%) 
Relationship 
status  
  
 
 
Education  
 
 
 
Employment 
 
Full-time 
 
46 (76.7%) 
 
56 (89.1%) 
 
103 (83.0%) 
Part-time 14 (23.3%) 7 (10.9%) 21 (17.0%)  
 
Smoking  
 
Non smoker 
 
38 (64.4%) 
 
26 (40.6%) 
 
64 (52.0%) 
Past smoker 14 (23.7%) 26 (40.6%) 40 (32.5%) 
Current Smoker 7 (11.9%) 12 (18.8%) 19 (15.4%) 
 
 
 
Exercise 
 
Rarely/Never 
 
4 (6.8%) 
 
6 (9.4%) 
 
10 (8.1%) 
Once a week or less 13 (22.1%) 16 (25.0%) 29 (23.4%) 
2-3 times a week 26 (44.1%) 24 (37.5%) 50 (40.7%) 
4-6 times a week 9 (15.3%) 11 (17.2%) 20 (16.3%) 
Every day 7 (11.9%) 7 (10.9%) 14 (11.4%) 
 
 
 
 
 
Alcohol   
 
None 
 
21 (35.6%) 
 
22 (34.4%) 
 
43 (35.0%) 
1-13 Units 31 (52.5%) 37 (57.8%) 68 (55.3%) 
14+ Units 7 (11.9%) 5 (7.8%) 12 (9.8%) 
 
 
 
BMI 
 
Mean (SD) 
 
25.66 (4.91) 
 
28.26 (4.12 
 
27.04 (4.67) 
						 27	
	 27	
Table	2.	Unadjusted	and	adjusted	group	differences	for	primary	and	secondary	outcomes		
	 	 SH-CBT	 NTWControl	 	 																			Adjusted	mean	difference	
	 Time	 N	
	
Mean		
	
SD	
	
N	
Mean	 SD	
Differ
ence	 SE	
p-
value	
Lowe
r	
95%C
I	
Uppe
r	
95%C
I	
Effect	
size	
HF/NS	
Problem	
Rating	 Baseline	 46	 6.25	 1.97	 60	 6.80	 1.90	 	 	 	 	 	 	
	 6	weeks	 44	 4.38	 2.21	 60	 6.16	 2.31	 -1.49	 0.32	 0.001	 -2.11	 -0.86	 0.77	
	 20	weeks	 42	 4.36	 2.29	 59	 5.80	 2.30	 -1.09	 0.40	 0.01	 -1.87	 -0.31	 0.56	
HF/NS	
Frequency	 Baseline	 46	 53.13	 34.34	 60	 54.28	 38.11	 	 	 	 	 	 	
	 6	weeks	 44	 40.59	 26.05	 59	 54.02	 43.00	
-
14.01	 5.05	 0.01	
-
23.91	 -4.10	 0.39	
	 20	weeks	 43	 34.28	 27.62	 59	 46.03	 37.92	
-
11.36	 5.26	 0.05	
-
21.66	 -1.05	 0.31	
WSAS	 Baseline	 46	 12.74	 9.77	 60	 12.67	 8.44	 	 	 	 	 	 	
	 6	weeks	 44	 8.52	 8.24	 59	 10.90	 8.09	 -2.36	 0.83	 0.01	 -3.98	 -0.74	 0.26	
	 20	weeks	 43	 8.65	 8.65	 57	 11.81	 8.39	 -2.89	 0.98	 0.01	 -4.80	 -0.98	 0.32	
Sleep	Quality	 Baseline	 44	 1.82	 0.81	 60	 1.85	 0.82	 	 	 	 	 	 	
	 6	weeks	 44	 1.30	 0.67	 58	 1.69	 0.78	 -0.41	 0.11	 0.001	 -0.63	 -0.20	 0.51	
	 20	weeks	 42	 1.40	 0.77	 58	 1.66	 0.78	 -0.24	 0.10	 0.05	 -0.44	 -0.03	 0.29	
WHQ	
anxiety/depre
ssion	 Baseline	 45	 67.53	 22.12	 60	 63.01	 19.97	 	 	 	 	 	 	
	 6	weeks	 44	 70.90	 22.30	 60	 64.12	 22.31	 2.88	 2.59	 ns	 -2.20	 7.96	 0.14	
	 20	weeks	 42	 74.85	 23.97	 58	 66.10	 21.42	 4.81	 2.78	 ns	 -0.64	 10.26	 0.23	
WHQ	
wellbeing	 Baseline	 45	 71.11	 15.65	 60	 66.94	 19.47	 	 	 	 	 	 	
	 6	weeks	 44	 71.40	 19.72	 60	 67.92	 19.58	 1.70	 2.55	 ns	 -3.31	 6.71	 0.09	
	 20	weeks	 42	 75.79	 16.44	 57	 67.54	 17.30	 6.62	 2.40	 0.01	 1.91	 11.33	 0.37	
WHQ	somatic	
symptoms	 Baseline	 45	 50.37	 23.93	 60	 47.67	 21.43	 	 	 	 	 	 	
	 6	weeks	 44	 53.48	 24.42	 60	 49.22	 22.74	 2.71	 3.11	 ns	 -3.39	 8.80	 0.12	
	 20	weeks	 42	 58.41	 22.47	 57	 49.94	 20.04	 8.38	 2.80	 0.01	 2.90	 13.86	 0.37	
WHQ	memory	
&	
concentration	 Baseline	 45	 45.92	 28.09	 60	 41.31	 24.39	 	 	 	 	 	 	
	 6	weeks	 44	 48.47	 26.91	 60	 42.41	 24.24	 3.07	 3.19	 ns	 -3.18	 9.33	 0.12	
	 20	weeks	 42	 51.33	 25.97	 57	 44.25	 23.15	 4.58	 3.03	 ns	 -1.36	 10.52	 0.18	
WHQ	sleep	
problems	 Baseline	 44	 34.09	 25.66	 60	 37.78	 26.01	 	 	 	 	 	 	
	 6	weeks	 44	 46.97	 27.91	 60	 37.22	 26.10	 12.75	 3.22	 0.001	 6.45	 19.06	 0.49	
	 20	weeks	 42	 48.41	 21.72	 56	 40.77	 30.47	 12.39	 3.79	 0.001	 4.96	 19.82	 0.48	
MRQ	negative	
impact	 Baseline	 46	 2.17	 0.73	 60	 2.27	 0.83	 	 	 	 	 	 	
	 6	weeks	 43	 2.13	 0.91	 60	 2.45	 0.77	 -0.23	 0.11	 0.05	 -0.45	 -0.01	 0.29	
	 20	weeks	 43	 2.09	 0.84	 59	 2.38	 0.69	 -0.21	 0.10	 0.05	 -0.41	 -0.01	 0.27	
						 28	
	 28	
MRQ	relief	 Baseline	 46	 2.52	 0.82	 60	 2.37	 0.96	 	 	 	 	 	 	
	 6	weeks	 43	 2.64	 0.95	 60	 2.50	 0.95	 0.03	 0.13	 ns	 -0.22	 0.29	 0.04	
	 20	weeks	 43	 2.70	 0.84	 59	 2.37	 1.00	 0.25	 0.11	 0.024	 0.03	 0.46	 0.28	
MRQ	new	
phase	 Baseline	 46	 1.72	 0.92	 60	 1.73	 0.87	 	 	 	 	 	 	
	 6	weeks	 43	 2.13	 0.77	 60	 1.71	 0.91	 0.41	 0.12	 0.001	 0.17	 0.65	 0.46	
	 20	weeks	 43	 2.22	 0.74	 59	 1.89	 0.76	 0.29	 0.11	 0.01	 0.08	 0.51	 0.33	
MRQ	
control/cure	 Baseline	 46	 2.11	 0.63	 60	 1.94	 0.90	 	 	 	 	 	 	
	 6	weeks	 43	 2.82	 0.81	 60	 2.05	 0.84	 0.64	 0.11	 0.001	 0.43	 0.86	 0.81	
	 20	weeks	 43	 2.88	 0.65	 59	 2.10	 0.80	 0.66	 0.11	 0.001	 0.44	 0.88	 0.83	
MRQ	identity	 Baseline	 46	 17.17	 8.28	 60	 15.80	 8.00	 	 	 	 	 	 	
	 6	weeks	 43	 16.35	 9.08	 60	 15.28	 7.98	 -0.22	 1.07	 ns	 -2.31	 1.87	 0.03	
	 20	weeks	 43	 16.40	 7.52	 59	 15.97	 8.61	 -0.41	 1.08	 ns	 -2.53	 1.71	 0.05	
HF	social	
beliefs	 Baseline	 46	 2.35	 1.67	 60	 2.30	 1.37	 	 	 	 	 	 	
	 6	weeks	 44	 1.59	 1.35	 60	 2.40	 1.38	 -0.80	 0.15	 0.001	 -1.09	 -0.51	 0.53	
	 20	weeks	 42	 1.55	 1.27	 57	 2.24	 1.39	 -0.64	 0.14	 0.001	 -0.91	 -0.37	 0.43	
HF	
coping/contro
l	beliefs	 Baseline	 46	 2.26	 1.22	 60	 2.45	 1.06	 	 	 	 	 	 	
	 6	weeks	 44	 1.57	 1.14	 60	 2.31	 1.17	 -0.60	 0.16	 0.001	 -0.91	 -0.29	 0.53	
	 20	weeks	 42	 1.77	 1.23	 58	 2.29	 1.20	 -0.47	 0.18	 0.01	 -0.83	 -0.11	 0.42	
NS/sleep	
beliefs	 Baseline	 46	 2.08	 1.09	 60	 2.42	 1.33	 	 	 	 	 	 	
	 6	weeks	 44	 1.29	 1.09	 60	 2.36	 1.41	 -0.90	 0.16	 0.001	 -1.21	 -0.58	 0.73	
	 20	weeks	 42	 1.26	 0.90	 57	 2.08	 1.31	 -0.64	 0.16	 0.001	 -0.95	 -0.33	 0.52	
HF/NS	
avoidant	
behaviours	 Baseline	 46	 0.75	 1.03	 60	 1.19	 1.41	 	 	 	 	 	 	
	 6	weeks	 44	 0.65	 1.00	 60	 1.21	 1.28	 -0.25	 0.15	 0.05	 -0.54	 0.04	 0.20	
	 20	weeks	 42	 0.79	 1.03	 57	 1.25	 1.51	 -0.16	 0.20	 ns	 -0.55	 0.23	 0.13	
HF/NS	
positive	
behaviours	 Baseline	 46	 3.34	 1.01	 60	 3.13	 1.19	 	 	 	 	 	 	
	 6	weeks	 44	 3.67	 0.86	 60	 3.11	 1.13	 0.43	 0.14	 0.01	 0.15	 0.71	 0.39	
	 20	weeks	 42	 3.64	 1.07	 58	 3.13	 1.17	 0.41	 0.18	 0.05	 0.06	 0.75	 0.37	
Absenteeism	
(days),	4	
weeks	 Baseline	 46	 1.17	 3.93	 60	 2.20	 4.25	 	 	 	 	 	 	
	 6	weeks	 46	 0.50	 2.25	 60	 1.13	 2.16	 -0.54	 0.44	 ns	 -1.40	 0.32	 0.13	
						 29	
	 29	
	 20	weeks	 46	 0.70	 3.00	 60	 1.43	 3.27	 -0.64	 0.55	 ns	 -1.71	 0.43	 0.16	
SPS	
Presenteeism	 Baseline	 46	 20.24	 6.34	 60	 18.67	 6.40	 	 	 	 	 	 	
	 6	weeks	 43	 22.12	 7.16	 59	 19.36	 6.93	 1.64	 0.90	 ns	 -0.13	 3.41	 0.26	
	 20	weeks	 43	 23.21	 5.84	 57	 18.18	 7.18	 4.18	 0.80	 0.001	 2.60	 5.76	 0.65	
Turnover	
intention	 Baseline	 46	 2.43	 0.97	 60	 2.67	 0.96	 	 	 	 	 	 	
	 6	weeks	 43	 2.32	 1.02	 59	 2.67	 0.90	 -0.20	 0.12	 ns	 -0.43	 0.03	 -0.21	
	 20	weeks	 42	 2.48	 1.06	 58	 2.50	 0.93	 0.09	 0.12	 ns	 0.14	 0.31	 0.09	
Job	
performance	 Baseline	 46	 4.07	 0.83	 59	 4.07	 0.93	 	 	 	 	 	 	
	 6	weeks	 44	 4.20	 0.76	 60	 4.18	 0.83	 -0.02	 0.12	 ns	 -0.25	 0.22	 -0.02	
	 20	weeks	 43	 4.30	 0.71	 59	 4.10	 0.74	 0.16	 0.12	 ns	 -0.07	 0.40	 0.19								
 																		
						 30	
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Figure 1. Flow chart of trial 
 Figure	2.	Standard	mean	differences	between	SH-CBT	vs	NTWC	groups	in	HFNS	problem	rating	and	frequency,	interference	(WSAS),	sleep	quality,	menopause	appraisals	and	HFNS	beliefs	and	behaviours.	Positive	values	favour	intervention.		Figure	3.	Standard	mean	differences	between	SH-CBT	vs	NTWC	groups	in	work	related	variables.	Positive	values	favour	intervention. 																															
						 31	
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   Screened for Eligibility (n=172)   
 
 
Enrolment 
     Excluded (n=27) 
Problematic HF/NS <2months,  
<10 per week (n=21) 
Did not want to participate (n=2) 
Age <45 years (n=4) 
 
 
 Consent Baseline assessment 
(n=145) 
Information sheet and consent 
form and baseline questionnaires. 
  Excluded (n=21)   
Lack of consent 
 
      
  Randomised (n=124) 
Baseline questionnaire received. 
Randomization, stratified by 
organisation 1:1 
  
       
 
 
Allocation: 
Participants 
Organisations 
 SH-CBT (n=60) 
Organisation 1 (n=7) 
 Organisation 2 (n=19) 
 Organisation 3 (n=10) 
Organisation 4 (n=8) 
Organisation 5 (n=3) 
Organisation 6 (n=2) 
Organisation 7 (n=4) 
Organisation 8 (n=7) 
 NTWC (n=64) 
Organisation 1 (n=13) 
Organisation 2 (n=19) 
Organisation 3 (n=7) 
Organisation 4 (n=7) 
Organisation 5 (n=2) 
Organisation 6 (n=6) 
Organisation 7 (n=4) 
Organisation 8 (n=6) 
 
 
       
  
 
6 
week follow-
up (n=104) 
Lost to follow-
up (n=20) 
 
 Group sample (n=44) 
Lost to follow-up (n=16): 
Unable to contact (n=2) 
Qu not returned (n=5) 
Time constraints (n=4) 
Ill health/personal (n=4)  
No more symptoms (n=1)  
 Group sample (n=60) 
Lost to follow-up (n=4): 
Sought other treatment (n=1) 
Not contactable (n=1) 
Qu not returned (n=1) 
Time constraints (n=1) 
 
 
       
  
20 week 
follow-up 
(n=102) 
 Group sample (n=43) 
Lost to follow-up (n=3): 
Completed Qu at 20 but 
not 6 weeks (n=2) 
Qu not returned (n=2) 
Feeling overwhelmed (n=1) 
 Group sample (n=59) 
Lost to follow-up (n=1): 
Time constraints (n=1) 
 
Lost to follow-
up (n=2) 
Analysed  
(n=106) 
 Total analysed  (n=46) 
Excluded (n=14) 
 Total analysed  (n=60) 
Excluded (n=4) 
  
						 32	
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HFNS Problem Rating
HFNS frequency
WSAS
Sleep quality
MRQ negative impact
MRQ relief
MRQ new phase
MRQ control cure
HF beliefs in social context
HF beliefs coping/control
Beliefs about NS/sleep
Avoidance behaviours
Positive coping behaviours
-.5 -.2 0 .2 .5 .8 1.2
                                         Standardised mean difference
6 weeks
20 weeks
						 33	
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